Envoy Medical Faces Delisting Concerns
Ticker: COCHW · Form: 8-K · Filed: Nov 25, 2025 · CIK: 1840877
Sentiment: bearish
Topics: delisting, listing-standards
TL;DR
Envoy Medical might be delisted, check their listing status ASAP.
AI Summary
Envoy Medical, Inc. filed an 8-K on November 25, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The earliest event reported was on November 19, 2025. The company, previously known as Anzu Special Acquisition Corp I, is incorporated in Delaware and operates in the orthopedic, prosthetic & surgical appliances & supplies industry.
Why It Matters
This filing indicates potential issues with Envoy Medical's continued listing on an exchange, which could impact its stock trading and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's ongoing operations and stock viability.
Key Players & Entities
- Envoy Medical, Inc. (company) — Registrant
- Anzu Special Acquisition Corp I (company) — Former company name
- November 19, 2025 (date) — Earliest event reported
- November 25, 2025 (date) — Date of report
FAQ
What specific listing rule or standard has Envoy Medical, Inc. failed to satisfy?
The filing does not specify the exact rule or standard that Envoy Medical, Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
What is the earliest event date reported in this 8-K filing?
The earliest event reported in this 8-K filing is November 19, 2025.
When was this Form 8-K filed with the SEC?
This Form 8-K was filed with the SEC on November 25, 2025.
What was Envoy Medical, Inc.'s former company name?
Envoy Medical, Inc.'s former company name was Anzu Special Acquisition Corp I.
In which state is Envoy Medical, Inc. incorporated?
Envoy Medical, Inc. is incorporated in Delaware.
Filing Stats: 749 words · 3 min read · ~2 pages · Grade level 13.4 · Accepted 2025-11-25 16:01:53
Key Financial Figures
- $0.0001 — tered Class A Common Stock, par value $0.0001 per share COCH The Nasdaq Stock Mar
- $11.50 — A Common Stock at an exercise price of $11.50 per share COCHW The Nasdaq Stock Ma
- $1.00 m — Stock"), has failed to comply with the $1.00 minimum bid price required for continued
- $1.00 — of the Common Stock must meet or exceed $1.00 per share for a minimum of ten consecut
Filing Documents
- ea026718501-8k_envoy.htm (8-K) — 26KB
- 0001213900-25-114725.txt ( ) — 233KB
- coch-20251119.xsd (EX-101.SCH) — 4KB
- coch-20251119_def.xml (EX-101.DEF) — 26KB
- coch-20251119_lab.xml (EX-101.LAB) — 36KB
- coch-20251119_pre.xml (EX-101.PRE) — 25KB
- ea026718501-8k_envoy_htm.xml (XML) — 6KB
01. Notice of Delisting or Failure to Satisfy a Continued
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 19, 2025, Envoy Medical, Inc. (the "Company") received a staff determination notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"), informing the Company that its Class A Common Stock, par value $0.0001 per share (the "Common Stock"), has failed to comply with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) for the 30 consecutive business days prior to the date of the Notice. The Notice has no immediate effect on the listing of the Common Stock on The Nasdaq Capital Market. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial compliance period of 180 calendar days, or until May 18, 2026 (the "Compliance Date"), to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Common Stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days prior to the Compliance Date. If the Company is unable to regain compliance by the Compliance Date, the Company may be eligible for an additional 180 calendar day compliance period to demonstrate compliance with the bid price requirement. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice to Nasdaq of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Company does not qualify for the second compliance period or fails to regain compliance during the second 180-day period, Nasdaq will notify the Company of its determination to delist the Common Stock, at which po
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENVOY MEDICAL, INC. November 25, 2025 By: /s/ Brent Lucas Brent Lucas Chief Executive Officer